reblozyl
bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - muut anemialääkkeet - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.
longin sitruuna 3 mg imeskelytabletti
orion corporation - benzydamine hydrochloride - imeskelytabletti - 3 mg - bentsydamiini
zysils sitruuna 3 mg imeskelytabletti
teva b.v. - benzydamine hydrochloride - imeskelytabletti - 3 mg - bentsydamiini
zysils appelsiini-hunaja 3 mg imeskelytabletti
teva b.v. - benzydamine hydrochloride - imeskelytabletti - 3 mg - bentsydamiini
flusils hunaja-sitruuna 8.75 mg imeskelytabletti
teva b.v. - flurbiprofen - imeskelytabletti - 8.75 mg - flurbiprofeeni
tenoblock 100 mg tabletti
takeda oy takeda oy - atenololum - tabletti - 100 mg - atenololi
tenoblock 50 mg tabletti
takeda oy takeda oy - atenololum - tabletti - 50 mg - atenololi
tenoblock 25 mg tabletti
takeda oy takeda oy - atenololum - tabletti - 25 mg - atenololi
vpriv
takeda pharmaceuticals international ag ireland branch - velagluksaasia alfa - gaucherin tauti - muut ruuansulatuselimistön sairauksien ja aineenvaihduntasairauksien lääkkeet, - vpriv on tarkoitettu pitkäaikaiseen entsyymikorvaushoitoon (ert) tyypin 1 gaucher-tautia sairastavilla potilailla.